Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 864962, 4 pages
Research Article

The Economic Burden of HIV/AIDS and Myocardial Infarction Treatment in Brazil

1Department of Internal Medicine, State University of Rio de Janeiro, Boulevard 28 de Setembro, No. 77, Room 329, 20551-030 Rio de Janeiro, RJ, Brazil
2National Institute of Science and Technology for Health Technology Assessment (IATS), CNPq, Rua Ramiro Barcelos, No. 2359, 90035-903 Porto Alegre, RS, Brazil

Received 2 August 2013; Accepted 30 September 2013

Academic Editors: S. C. Fuchs and M. B. Moreira

Copyright © 2013 Denizar Vianna Araújo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To analyze the expenses of HIV/AIDS and acute myocardial infarction (AMI) treatment in Brazil. Methods. A search in the Brazilian epidemiological database (DATASUS) on AMI and AIDS hospitalizations and their costs was done from January 1998 to December 2011. The number of HIV/AIDS cases and antiretroviral treatment (ART) costs was obtained from public Brazilian databases. Results. In 5 years, HIV/AIDS cases increased 38.5%, mainly in patients aged 25–49. There were 180,640 patients in ART in 2007 at a cost of R$ 3,920 per patient/year. The hospitalizations due to AIDS were stable over the last 13 years; however, the hospitalizations due to AMI have increased 78%. In 2007, the expenses with hospitalizations for HIV/AIDS and AMI (25–49 years) were approximately 0.12 and 1.52% of the Ministry of Health budget allocated to reimburse inpatient costs. The expenses on ART totaled 1.5% of the total budget (all age groups). Conclusion. The prevalence of HIV/AIDS is still increasing in Brazil. There are scientific evidences suggesting an increased incidence of AIM in this population. Considering the high costs for the treatment of both diseases, an economic analysis is important to alert health managers to strengthen the preventive measures to guarantee the financial sustainability of such treatment.